Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.68 +0.82 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
34 35 Next >
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday 
Via Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
The market sell-off over the past year hasn't stopped these healthcare giants from rallying. 
Via The Motley Fool
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. 
Via The Motley Fool
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
Is Sanofi Stock a Buy Now?
The pharma giant has outperformed the broader market over the past 12 months. 
Via The Motley Fool
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
Why Shares of Regeneron Are Rising Thursday
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Via Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Benzinga 
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. 
Via The Motley Fool
What's Going On With Sanofi Stock After Hours?
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States  
Via Benzinga
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.